Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors

Kerry J Rodabaugh, R. B. Biggs, J. A. Qureshi, A. J. Barrett, W. R. Welch, D. A. Bell, R. S. Berkowitz, S. C. Mok

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

We used PCR amplification of tandem repeats to study the pattern of allelic loss in borderline and invasive ovarian epithelial tumors using 12 primer pairs to generate a detailed deletion map of chromosome 9p. In the invasive ovarian carcinomas, there were three regions displaying high frequency of loss of heterozygosity (LOH) ranging from 31-38%. In contrast, LOH was a rare event among the borderline ovarian tumors, with one region revealing a rate of 20% and the remaining regions only 0-8% LOH. Therefore, allelic loss does not seem to be important for the development of borderline ovarian tumors. We also examined p16 gene expression and mutations in ovarian cancer cell lines and invasive and borderline ovarian tumor tissues. Southern blot analysis revealed no losses of the p16 gene in either the invasive or borderline ovarian tumors. However, the ovarian carcinoma cell lines showed a 50% homozygous deletion rate. SSCP analysis detected a mobility shift in only one (borderline) tumor. Since the primary invasive ovarian tumors did not show any deletions or mutations, it appears that p16 does not play a role in the pathogenesis of these tumors.

Original languageEnglish (US)
Pages (from-to)1249-1254
Number of pages6
JournalOncogene
Volume11
Issue number7
StatePublished - Jan 1 1995

Fingerprint

p16 Genes
Chromosome Deletion
Chromosome Mapping
Loss of Heterozygosity
Neoplasms
Carcinoma
Single-Stranded Conformational Polymorphism
Cell Line
Tandem Repeat Sequences
Sequence Deletion
Southern Blotting
Ovarian Neoplasms
Gene Expression
Polymerase Chain Reaction
Mutation

Keywords

  • Borderline ovarian tumor
  • Chromosome 9p
  • Loss of heterozygosity
  • Ovarian cancer
  • p16 gene

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Biology

Cite this

Rodabaugh, K. J., Biggs, R. B., Qureshi, J. A., Barrett, A. J., Welch, W. R., Bell, D. A., ... Mok, S. C. (1995). Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors. Oncogene, 11(7), 1249-1254.

Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors. / Rodabaugh, Kerry J; Biggs, R. B.; Qureshi, J. A.; Barrett, A. J.; Welch, W. R.; Bell, D. A.; Berkowitz, R. S.; Mok, S. C.

In: Oncogene, Vol. 11, No. 7, 01.01.1995, p. 1249-1254.

Research output: Contribution to journalArticle

Rodabaugh, KJ, Biggs, RB, Qureshi, JA, Barrett, AJ, Welch, WR, Bell, DA, Berkowitz, RS & Mok, SC 1995, 'Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors', Oncogene, vol. 11, no. 7, pp. 1249-1254.
Rodabaugh, Kerry J ; Biggs, R. B. ; Qureshi, J. A. ; Barrett, A. J. ; Welch, W. R. ; Bell, D. A. ; Berkowitz, R. S. ; Mok, S. C. / Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors. In: Oncogene. 1995 ; Vol. 11, No. 7. pp. 1249-1254.
@article{e008a8e836da43a8b1cb42c6d79b8d76,
title = "Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors",
abstract = "We used PCR amplification of tandem repeats to study the pattern of allelic loss in borderline and invasive ovarian epithelial tumors using 12 primer pairs to generate a detailed deletion map of chromosome 9p. In the invasive ovarian carcinomas, there were three regions displaying high frequency of loss of heterozygosity (LOH) ranging from 31-38{\%}. In contrast, LOH was a rare event among the borderline ovarian tumors, with one region revealing a rate of 20{\%} and the remaining regions only 0-8{\%} LOH. Therefore, allelic loss does not seem to be important for the development of borderline ovarian tumors. We also examined p16 gene expression and mutations in ovarian cancer cell lines and invasive and borderline ovarian tumor tissues. Southern blot analysis revealed no losses of the p16 gene in either the invasive or borderline ovarian tumors. However, the ovarian carcinoma cell lines showed a 50{\%} homozygous deletion rate. SSCP analysis detected a mobility shift in only one (borderline) tumor. Since the primary invasive ovarian tumors did not show any deletions or mutations, it appears that p16 does not play a role in the pathogenesis of these tumors.",
keywords = "Borderline ovarian tumor, Chromosome 9p, Loss of heterozygosity, Ovarian cancer, p16 gene",
author = "Rodabaugh, {Kerry J} and Biggs, {R. B.} and Qureshi, {J. A.} and Barrett, {A. J.} and Welch, {W. R.} and Bell, {D. A.} and Berkowitz, {R. S.} and Mok, {S. C.}",
year = "1995",
month = "1",
day = "1",
language = "English (US)",
volume = "11",
pages = "1249--1254",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors

AU - Rodabaugh, Kerry J

AU - Biggs, R. B.

AU - Qureshi, J. A.

AU - Barrett, A. J.

AU - Welch, W. R.

AU - Bell, D. A.

AU - Berkowitz, R. S.

AU - Mok, S. C.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - We used PCR amplification of tandem repeats to study the pattern of allelic loss in borderline and invasive ovarian epithelial tumors using 12 primer pairs to generate a detailed deletion map of chromosome 9p. In the invasive ovarian carcinomas, there were three regions displaying high frequency of loss of heterozygosity (LOH) ranging from 31-38%. In contrast, LOH was a rare event among the borderline ovarian tumors, with one region revealing a rate of 20% and the remaining regions only 0-8% LOH. Therefore, allelic loss does not seem to be important for the development of borderline ovarian tumors. We also examined p16 gene expression and mutations in ovarian cancer cell lines and invasive and borderline ovarian tumor tissues. Southern blot analysis revealed no losses of the p16 gene in either the invasive or borderline ovarian tumors. However, the ovarian carcinoma cell lines showed a 50% homozygous deletion rate. SSCP analysis detected a mobility shift in only one (borderline) tumor. Since the primary invasive ovarian tumors did not show any deletions or mutations, it appears that p16 does not play a role in the pathogenesis of these tumors.

AB - We used PCR amplification of tandem repeats to study the pattern of allelic loss in borderline and invasive ovarian epithelial tumors using 12 primer pairs to generate a detailed deletion map of chromosome 9p. In the invasive ovarian carcinomas, there were three regions displaying high frequency of loss of heterozygosity (LOH) ranging from 31-38%. In contrast, LOH was a rare event among the borderline ovarian tumors, with one region revealing a rate of 20% and the remaining regions only 0-8% LOH. Therefore, allelic loss does not seem to be important for the development of borderline ovarian tumors. We also examined p16 gene expression and mutations in ovarian cancer cell lines and invasive and borderline ovarian tumor tissues. Southern blot analysis revealed no losses of the p16 gene in either the invasive or borderline ovarian tumors. However, the ovarian carcinoma cell lines showed a 50% homozygous deletion rate. SSCP analysis detected a mobility shift in only one (borderline) tumor. Since the primary invasive ovarian tumors did not show any deletions or mutations, it appears that p16 does not play a role in the pathogenesis of these tumors.

KW - Borderline ovarian tumor

KW - Chromosome 9p

KW - Loss of heterozygosity

KW - Ovarian cancer

KW - p16 gene

UR - http://www.scopus.com/inward/record.url?scp=0028850649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028850649&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 1249

EP - 1254

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 7

ER -